Growth through partnerships Mercodia is expanding its global footprint with new distribution partnerships in Africa (Botswana, Namibia, South Africa, Uganda, Zambia) and a recent U.S. office expansion, signaling opportunities for channel partners and regional sales outreach.

Clinical and preclinical With GLP-compliant laboratories and services spanning preclinical to clinical phases, Mercodia offers bioanalytical assays and CRO capabilities that can be positioned to pharma and biotech clients seeking end-to-end analytical support for large molecule therapeutics and biomarkers.

Innovative assays Recent launches of the HNL Homodimer ELISA and the Insulin MBeads Assay highlight a track record of new, high-demand immunoassays, providing opportunities to upsell to existing customers and attract researchers pursuing cutting-edge biomarker measurements.

Quality and reliability Mercodia’s Di Gasell recognitions and long-standing reputation for quality and regulatory compliance offer a strong trust signal for life science buyers, enabling value-focused conversations around data integrity, compliance, and risk mitigation.

U.S. market focus The U.S. expansion complements their European base, presenting a clear path for targeted sales plays with pharmaceutical and academic accounts seeking local expertise, faster turnaround, and cost-effective bioanalytical services in a competitive landscape.